Evidence map›Paper›PMID 36459185›Full record

Observational studyClinical research in cardiology : official journal of the German Cardiac Society2023

RAS inhibitors and renal and general mortality in patients with heart failure supported by left ventricular assist devices: a registry study.

Gianmarco Lombardi, Alessia Gambaro, Flavio Luciano Ribichini, Pietro Manuel Ferraro, Giovanni Gambaro

Abstract readObservational Study
PubMed Publisher
In one paragraph

Observational study in Clinical research in cardiology : official journal of the German Cardiac Society, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.2field-weighted citation impact, top 52% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Gianmarco Lombardi *U.O.C. Nefrologia, Department of Medicine, Azienda Ospedaliera Universitaria Integrata di Verona, University of Verona, Piazzale Aristide Stefani, 1, 37126, Verona, Italy. gianmarco.lombardi@univr.it.ORCID http://orcid.org/0000-0003-2298-1420
Alessia Gambaro *U.O.C. Cardiologia, Department of Medicine, Azienda Ospedaliera Universitaria Integrata di Verona, University of Verona, Verona, Italy.
Flavio Luciano RibichiniU.O.C. Cardiologia, Department of Medicine, Azienda Ospedaliera Universitaria Integrata di Verona, University of Verona, Verona, Italy.
Pietro Manuel FerraroU.O.S. Terapia Conservativa della Malattia Renale Cronica, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italia.
Giovanni GambaroU.O.C. Nefrologia, Department of Medicine, Azienda Ospedaliera Universitaria Integrata di Verona, University of Verona, Piazzale Aristide Stefani, 1, 37126, Verona, Italy.
University of Verona · ITUniversità Cattolica del Sacro Cuore · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe aim of our study was to analyze the association between renin-angiotensin system inhibitor (RASi) therapy and renal outcomes and mortality in patients with heart failure (HF) supported by left ventricular assist device (LVAD) using a large, nationwide prospective cohort. To date, no studies have comprehensively analyzed the association between RASi and renal outcomes and mortality in patients with HF supported by LVAD.

methodsWe performed a retrospective observational study on LVAD patients in the Interagency Registry for Mechanically Assisted Circulatory Support. The main outcome was a composite of renal event and all-cause mortality. Secondary outcomes were the individual components of the composite outcome. A renal event was defined as a composite of doubling serum creatinine, eGFR decrease ≥ 40%, or need for dialysis. The exposure of interest was RASi therapy, updated during follow-up. Cox regression models adjusted for potential confounders were used to estimate the association between time-updated RASi therapy and the outcomes of interest.

resultsThe analysis included 6448 patients. During a median follow-up of 12.7 months (IQR 19.8 months), 1632 patients developed the composite outcome. RASi therapy was associated with a lower risk of developing the composite outcome (HR 0.61, 95% CI 0.55, 0.68, P < 0.001). A significant association was confirmed between RASi therapy and renal outcomes (HR 0.74, 95% CI 0.61, 0.89, P = 0.002) and all-cause mortality (HR 0.56, 95% CI 0.50, 0.63, P < 0.001).

conclusionsOur data suggest a beneficial role of RASi therapy on renal function and all-cause mortality in patients with HF supported by LVAD.

Indexed as

Antineoplastic AgentsHeart-Assist DevicesHeart FailureHumansKidneyProspective StudiesRegistriesTreatment OutcomeAntineoplastic AgentsAll-cause mortalityEpidemiological studyLVAD patientsRASi therapyRenal outcome

Identifiers

PMID36459185
OpenAlexW4310597257

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.